Aclaris Therapeutics Sees 62% Q4 Gain, Still Down 83% Over Three Years
ByAinvest
Sunday, Nov 2, 2025 7:53 am ET1min read
ACRS--
Aclaris Therapeutics' (ACRS) stock has risen 62% in the last quarter, but its market cap has only increased by $40m in the past 7 days. Despite this, the company's three-year returns have been poor, with investors down 83%. The company's revenue has dropped 0.8% per year over the last three years, and its share price has fallen 22% annually. Insiders have been buying shares, but future earnings will be crucial to determining whether shareholders will make money.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet